Project Grant HT94252411118
Award Date
9/30/24
Completion Date
3/13/25
Dollars Obligated
$739K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
South Africa
Similar Awards
The federal Project Grant award of $584,828 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" initiative at the University of Nairobi in Kenya. This research project aims to advance prostate cancer precision health and improve treatment outcomes in Sub-Saharan Africa. The award will...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), awarded a $1,839,317 project grant to the University of Illinois to conduct the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" project. This 2-year research project, starting on September 30, 2024, aims to evaluate the interrelated roles of environmental factors and...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
The Defense Health Agency awarded a $1,346,633 Project Grant to the George Washington University under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "A PRIMARY ROLE FOR THE CIRCULATORY MICROENVIRONMENT IN AFRICAN AMERICAN PROSTATE CANCER DISPARITIES?" from May 15, 2023 to May 14, 2026. As the prime awardee, George Washington University will investigate medical solutions for prostate cancer disparities affecting African...
This $260,250 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by Health Research, Inc. on the role of the SLC45A3-ELK4 chimera as a molecular determinant of prostate cancer health disparities. The two-year research project aims to advance the understanding of prostate cancer biology and genetic mechanisms, with the potential to lead to improved prevention, diagnosis, and treatment...
The University of Sydney, through its International Clinical Trials Symposium division, was awarded a $3,580,840 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA," will support advanced biomedical research initiatives focused on...
This federal Project Grant award in the amount of $1,927,373.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to develop targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The primary awardee is the Fred Hutchinson Cancer Center, a prominent non-profit medical research organization located in Seattle, Washington. The grant has a performance...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This federal Project Grant award of $1,235,845.00 was provided by the Defense Health Agency, which administers the Military Medical Research and Development (CFDA 12.420) program. The grant is for a project titled "LEVERAGING DATA SCIENCE METHODS TO DELIVER INDIVIDUALIZED TREATMENT EFFECTS IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER", with a performance period from August 15, 2025 to August 14, 2028. The University of Illinois, the awardee, will leverage data science methods to...